“Drying of Opzelura® (Ruxolitinib) Cream 1.5%: Implications for Clinical and Real-World Use”. 2024. SKIN The Journal of Cutaneous Medicine 8 (6): s454. https://doi.org/10.25251/skin.8.supp.454.